# idiopathic pulmonary fibrosis (IPF) - claude-opus-4-8

- Benchmark system: raw
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 
- Completion tokens: 
- Reasoning tokens: 
- Total tokens: 
- API requests reported: 
- Elapsed seconds: 122.144
- Final benchmark system: raw; file rank 4/5; original repeat 6; model vendor: Anthropic

---
# Multidimensional Interpretation of IPF Prognosis-Associated Transcriptomic Features

## 1. Overall Biological Interpretation

The prognostic transcriptomic signature in IPF lung tissue reveals a complex injury-response phenotype characterized by **epithelial dysfunction and aberrant regeneration**, **innate immune activation**, and **extracellular matrix remodeling**. The risk-associated genes (HR > 1) dominate the signal and converge on several interconnected processes: epithelial cell stress and abnormal differentiation, neutrophil-mediated inflammation, altered metabolic states, and fibroproliferative tissue remodeling. This is not simply a fibrosis signature but rather a profile of failed tissue repair, where activated epithelial programs and chronic inflammation collectively drive disease progression and mortality.

Several genes traditionally associated with epithelial homeostasis and barrier function (MUC1, SLC34A2, SFTPB, SFTA2) appear as risk factors, suggesting that their expression in this context may reflect aberrant regenerative attempts, epithelial metaplasia, or structural disorganization rather than protective function. The absence of a clear protective gene signature (HR < 1, except for LOC100128226 with uncertain annotation) underscores the unidirectional nature of transcriptomic risk in advanced IPF.

**Critical interpretive caution**: The extreme hazard ratios (HR > 10^20 or < 10^-20) for the first 10 genes, along with P = 0 and FDR = 0, indicate numerical instability, likely due to perfect separation, zero events in one stratum, or technical artifact. These genes should be excluded from biological interpretation pending data verification. The analysis below focuses on genes with biologically plausible effect sizes (HR ~2–4).

---

## 2. Core Biological Programs

### Program 1: **Epithelial Injury, Stress, and Aberrant Differentiation**
- **Direction**: Risk-associated (HR > 1)
- **Major supporting genes**: MUC1, SLC34A2, SFTPB, SFTA2, CEACAM6, CEACAM7, SLC7A11, PRSS8, MAL2, KRT17, KRT23, SPRR1A, MUC21, AGR3, PKP3
- **Relevant pathways**: 
  - GO: Epithelial cell differentiation (GO:0030855)
  - Reactome: Surfactant metabolism (R-HSA-5683826)
  - Hallmark: Epithelial-mesenchymal transition
- **Biological rationale**: Multiple genes encoding epithelial structural proteins, surfactant components (SFTPB, SFTA2, SLC34A2), mucins (MUC1, MUC21), keratins (KRT17, KRT23), and carcinoembryonic antigen-related molecules (CEACAM6, CEACAM7) are elevated and associated with poor prognosis. SLC34A2 is the sodium-phosphate cotransporter critical for alveolar type II cell function. SFTPB and SFTA2 are surfactant-associated proteins. The convergence of these markers suggests not normal epithelial function but rather **epithelial metaplasia, stress-induced reprogramming, or loss of normal alveolar architecture**. SLC7A11 (xCT, cystine/glutamate antiporter) indicates oxidative stress and altered redox metabolism. AGR3 and PRSS8 are associated with secretory and mucinous phenotypes. This collective signature likely reflects attempted but dysfunctional epithelial repair in the fibrotic niche.
- **Evidence strength**: Strong—supported by multiple independent genes within coherent biological pathways
- **Limitations**: Elevated expression of epithelial markers may reflect increased epithelial cell number, altered cell state, or stress responses; these possibilities cannot be distinguished without single-cell resolution or spatial profiling. The causal role of these genes in mortality versus their representation as markers of advanced disease remains unclear.

---

### Program 2: **Neutrophil Recruitment and Innate Immune Activation**
- **Direction**: Risk-associated (HR > 1)
- **Major supporting genes**: S100A12, S100A14, CXCL1, CXCL14, CXCR1, CCL7, SELL (L-selectin), CD177
- **Relevant pathways**: 
  - GO: Neutrophil chemotaxis (GO:0030593)
  - Reactome: Neutrophil degranulation (R-HSA-6798695)
  - KEGG: Chemokine signaling pathway (hsa04062)
- **Biological rationale**: S100A12 and S100A14 are damage-associated molecular patterns (DAMPs) released during inflammation and neutrophil activation. CXCL1 and CXCL14 are chemokines with neutrophil and monocyte chemotactic activity; CXCR1 is a receptor for CXCL8 (IL-8) expressed on neutrophils. CCL7 (MCP-3) recruits monocytes and other leukocytes. SELL (CD62L) is critical for neutrophil rolling and extravasation. CD177 is a neutrophil-specific glycoprotein upregulated during activation. The coordinated upregulation of these mediators suggests active neutrophilic inflammation, which has been associated with acute exacerbations and poor outcomes in IPF.
- **Evidence strength**: Strong—multiple chemokines, receptors, and neutrophil markers with convergent function
- **Limitations**: This signal may partially reflect increased neutrophil infiltration (composition effect) rather than intrinsic transcriptional changes in resident cells. Distinguishing neutrophil abundance from per-cell activation states requires deconvolution or histological validation. Neutrophilic inflammation may be secondary to epithelial injury rather than a primary driver.

---

### Program 3: **Growth Factor Signaling and Epithelial-Mesenchymal Crosstalk**
- **Direction**: Risk-associated (HR > 1)
- **Major supporting genes**: HGF, MET, NRG1, BMP6, HTRA1, SPRY2
- **Relevant pathways**: 
  - Reactome: Signaling by MET (R-HSA-6806834)
  - KEGG: MAPK signaling pathway (hsa04010)
  - GO: Regulation of epithelial to mesenchymal transition (GO:0010717)
- **Biological rationale**: HGF (hepatocyte growth factor) and its receptor MET are central to epithelial repair and regeneration but can also promote fibroblast activation and fibrosis when chronically elevated. NRG1 (neuregulin-1) signals through ErbB receptors and influences epithelial and mesenchymal behavior. BMP6 is a TGF-β superfamily member involved in matrix remodeling and fibrosis. HTRA1 is a secreted serine protease that modulates TGF-β signaling and ECM homeostasis; its upregulation in IPF lung tissue has been reported. SPRY2 is a negative regulator of receptor tyrosine kinase signaling, including MET and EGFR; its upregulation may represent a compensatory feedback mechanism in the setting of chronic growth factor stimulation. Together, these genes suggest dysregulated paracrine signaling between injured epithelium and activated mesenchyme.
- **Evidence strength**: Moderate to strong—genes are functionally linked and implicated in epithelial-mesenchymal interaction, though their exact roles may be context-dependent
- **Limitations**: The prognostic association of growth factor pathway components does not imply causality or therapeutic tractability. HGF/MET, for example, has context-dependent effects (profibrotic vs. antifibrotic) depending on timing, cellular source, and microenvironment. The presence of negative regulators (SPRY2) complicates pathway-level interpretation.

---

### Program 4: **Extracellular Matrix Remodeling and Fibroproliferation**
- **Direction**: Risk-associated (HR > 1)
- **Major supporting genes**: SPP1 (osteopontin), EFEMP1 (fibulin-3), SOD3, CHST15, HTRA1, STAB1, MMP25
- **Relevant pathways**: 
  - GO: Extracellular matrix organization (GO:0030198)
  - Reactome: Degradation of the extracellular matrix (R-HSA-1474228)
  - Hallmark: TGF-β signaling
- **Biological rationale**: SPP1 (osteopontin) is a matricellular protein strongly implicated in IPF pathogenesis, promoting fibroblast migration, macrophage recruitment, and matrix deposition. EFEMP1 (fibulin-3) is an ECM glycoprotein elevated in IPF and associated with fibrosis progression. SOD3 (extracellular superoxide dismutase) may reflect oxidative stress responses. CHST15 (carbohydrate sulfotransferase 15) modifies chondroitin sulfate and influences ECM composition. HTRA1 regulates ECM turnover. STAB1 (stabilin-1) is expressed on alternatively activated macrophages and endothelial cells involved in tissue remodeling. MMP25 is a membrane-type matrix metalloproteinase. Collectively, these genes indicate active ECM remodeling and fibroproliferative responses characteristic of progressive fibrosis.
- **Evidence strength**: Strong—SPP1 and EFEMP1 are well-established IPF biomarkers; supporting genes are mechanistically plausible
- **Limitations**: ECM gene expression may reflect fibroblast, macrophage, or epithelial sources. Pathway causality versus consequence of tissue remodeling is unclear. Not all matrix remodeling is pathologic; some may represent attempted repair.

---

### Program 5: **Metabolic Reprogramming and Lipid Handling**
- **Direction**: Risk-associated (HR > 1)
- **Major supporting genes**: CYP4F3, SLCO4A1, ACOX2, SLC6A8, SLC39A8, DYSF
- **Relevant pathways**: 
  - Reactome: Fatty acid metabolism (R-HSA-8978868)
  - GO: Lipid metabolic process (GO:0006629)
  - KEGG: Peroxisome (hsa04146)
- **Biological rationale**: CYP4F3 is a cytochrome P450 enzyme involved in leukotriene and eicosanoid metabolism. SLCO4A1 is an organic anion transporter that mediates uptake of prostaglandins and other signaling lipids. ACOX2 is a peroxisomal acyl-CoA oxidase involved in fatty acid beta-oxidation. SLC6A8 transports creatine, reflecting altered energy metabolism. SLC39A8 is a zinc transporter implicated in inflammatory responses. DYSF (dysferlin) is involved in membrane repair and vesicle trafficking, including lipid-rich vesicles. This set of genes suggests altered lipid metabolism, eicosanoid signaling, and cellular energetics, which may reflect metabolic adaptation to chronic injury and inflammation.
- **Evidence strength**: Moderate—genes are functionally coherent but less extensively studied in IPF compared to fibrosis and immune pathways
- **Limitations**: Metabolic reprogramming may be secondary to hypoxia, oxidative stress, or immune activation rather than a primary pathogenic mechanism. Cell-type specificity is unclear. The prognostic relevance of these pathways requires further validation.

---

## 3. Key Genes and Interaction Modules

### 1. **SPP1 (Osteopontin)** | HR = 3.40
- **Direction**: Risk-associated
- **Role**: Central matricellular protein in fibrosis, linking ECM remodeling, macrophage polarization, and epithelial-mesenchymal signaling. SPP1 is one of the most consistently elevated and prognostically significant genes in IPF across multiple studies.
- **Evidence type**: Direct dataset evidence, extensive disease-association evidence, pathway evidence
- **Interactions**: SPP1 interacts with integrins (αvβ3, αvβ5) and CD44; these interactions activate downstream signaling (FAK, PI3K/AKT, NF-κB) in fibroblasts, macrophages, and epithelial cells. (Protein interaction and regulatory evidence)

### 2. **MET and HGF** | HR = 2.53 (MET), 2.93 (HGF)
- **Direction**: Risk-associated
- **Role**: Receptor-ligand pair governing epithelial repair. Their co-elevation suggests sustained activation of HGF/MET signaling, which may reflect chronic injury-repair cycling rather than effective regeneration.
- **Interaction type**: Direct physical interaction (ligand-receptor)
- **Evidence**: Dataset evidence (both genes elevated), pathway evidence (Reactome MET signaling), literature evidence (HGF/MET dysregulation reported in IPF)

### 3. **HTRA1** | HR = 4.30
- **Direction**: Risk-associated
- **Role**: Serine protease that degrades ECM components and modulates TGF-β signaling. HTRA1 upregulation may represent a compensatory attempt to limit fibrosis or, conversely, contribute to matrix disorganization.
- **Evidence**: Dataset evidence (high HR), disease-association evidence (elevated in IPF lung tissue), pathway evidence (TGF-β regulation, ECM degradation)
- **Interactions**: HTRA1 can cleave fibulin-5, fibronectin, and other ECM proteins; it also inhibits TGF-β signaling by degrading its ligands. (Regulatory interaction)

### 4. **S100A12** | HR = 2.53
- **Direction**: Risk-associated
- **Role**: DAMP released by activated neutrophils and monocytes; signals through RAGE (receptor for advanced glycation end products) to amplify inflammation.
- **Evidence**: Dataset evidence, expression evidence (neutrophil-specific), pathway evidence (innate immune activation)
- **Interactions**: S100A12 binds RAGE and TLR4, triggering NF-κB and MAPK signaling. (Protein interaction and regulatory evidence)

### 5. **CEACAM6** | HR = 2.66
- **Direction**: Risk-associated
- **Role**: Glycosylphosphatidylinositol-anchored cell adhesion molecule upregulated in epithelial stress and cancer. Its elevation in IPF may reflect aberrant epithelial differentiation or metaplastic changes.
- **Evidence**: Dataset evidence, expression evidence (epithelial), disease-association evidence (elevated in lung injury models)
- **Interactions**: CEACAM6 can interact with integrins and other CEACAMs; these interactions influence cell adhesion, migration, and survival. (Protein interaction)

### 6. **SLC7A11 (xCT)** | HR = 3.52
- **Direction**: Risk-associated
- **Role**: Cystine/glutamate antiporter that supports glutathione synthesis and protects against oxidative stress. Paradoxically, its upregulation is associated with poor prognosis, possibly reflecting chronic oxidative burden or metabolic reprogramming.
- **Evidence**: Dataset evidence, pathway evidence (redox homeostasis), disease-association evidence (elevated in fibrotic lung)
- **Interactions**: SLC7A11 forms a heterodimer with SLC3A2 (CD98); this complex mediates cystine uptake. (Direct physical interaction)

### 7. **MERTK** | HR = 3.70
- **Direction**: Risk-associated
- **Role**: Tyrosine kinase receptor involved in efferocytosis (clearance of apoptotic cells) and regulation of macrophage polarization. Elevated MERTK may reflect increased apoptotic burden or altered macrophage function in fibrotic lung.
- **Evidence**: Dataset evidence, pathway evidence (efferocytosis, TAM receptor signaling), disease-association evidence (implicated in fibrosis)
- **Interactions**: MERTK binds Gas6 and Protein S, triggering anti-inflammatory and profibrotic signaling. (Ligand-receptor interaction)

### 8. **NRG1** | HR = 2.76
- **Direction**: Risk-associated
- **Role**: Growth factor signaling through ErbB receptors; influences epithelial and mesenchymal cell behavior. NRG1 has context-dependent roles in tissue repair and fibrosis.
- **Evidence**: Dataset evidence, pathway evidence (ErbB signaling), literature evidence (NRG1 dysregulation in lung injury)
- **Interactions**: NRG1 binds ErbB3 and ErbB4, which heterodimerize with ErbB2 to activate downstream pathways (PI3K/AKT, MAPK). (Ligand-receptor and regulatory interaction)

### 9. **EFEMP1 (Fibulin-3)** | HR = 2.33
- **Direction**: Risk-associated
- **Role**: ECM glycoprotein elevated in IPF serum and lung tissue; proposed as a diagnostic and prognostic biomarker. EFEMP1 modulates ECM assembly and cell-matrix interactions.
- **Evidence**: Dataset evidence, disease-association evidence (established IPF biomarker), pathway evidence (ECM organization)
- **Interactions**: EFEMP1 interacts with other ECM components (fibulin-5, tropoelastin) and may modulate integrin signaling. (Pathway co-membership and indirect interaction)

### 10. **MARCKS** | HR = 4.00
- **Direction**: Risk-associated
- **Role**: Myristoylated alanine-rich C-kinase substrate; regulates actin dynamics, cell motility, and membrane trafficking. MARCKS is implicated in fibroblast activation and epithelial plasticity.
- **Evidence**: Dataset evidence (high HR), pathway evidence (cytoskeletal regulation), literature evidence (elevated in fibrotic tissues)
- **Interactions**: MARCKS is phosphorylated by PKC, which regulates its binding to actin and phosphatidylinositol 4,5-bisphosphate (PIP2). (Regulatory interaction)

---

## 4. Validation Priorities

### Priority 1: **Epithelial cell-state heterogeneity and aberrant differentiation programs**
- **Classification**: Mechanistic hypothesis
- **Rationale**: The elevation of multiple epithelial markers (MUC1, CEACAM6, SFTPB, keratins) may reflect metaplastic or stress-induced epithelial phenotypes that drive fibrosis progression. Understanding the specific epithelial cell states contributing to this signature is critical for identifying therapeutic targets.
- **Current evidence**: Multiple risk-associated genes with epithelial expression; pathway coherence (epithelial differentiation, surfactant metabolism)
- **Supporting/conflicting evidence**: Literature supports epithelial dysfunction as central to IPF pathogenesis. However, whether specific metaplastic states (e.g., mucin-producing, KRT17+ basal-like) are causally linked to mortality is unresolved.
- **Next steps**: Single-cell RNA sequencing of IPF lung tissue to map epithelial cell states; correlate cell-state proportions with clinical outcomes; validate in independent cohorts
- **Conclusion status**: **Supported hypothesis**—multiple lines of evidence support epithelial dysfunction, but causal mechanisms require experimental validation

---

### Priority 2: **Neutrophilic inflammation as a driver of IPF progression**
- **Classification**: Mechanistic hypothesis / Biomarker
- **Rationale**: The neutrophil chemokine and activation signature (S100A12, CXCL1, CXCR1, CD177) suggests that neutrophilic inflammation contributes to poor prognosis. This is clinically relevant, as neutrophil-predominant inflammation is associated with acute exacerbations.
- **Current evidence**: Multiple neutrophil-associated genes with convergent function; pathway evidence (neutrophil chemotaxis, degranulation)
- **Supporting evidence**: Bronchoalveolar lavage studies show neutrophilia in IPF predicts poor outcomes. S100A12 is elevated in IPF serum.
- **Conflicting evidence**: IPF is traditionally considered a non-inflammatory fibrosis; the role of neutrophils versus macrophages is debated.
- **Next steps**: Validate neutrophil abundance by immunohistochemistry or flow cytometry; correlate with mortality; test anti-neutrophil therapies in preclinical models
- **Conclusion status**: **Supported hypothesis**—observational evidence is strong, but causality and therapeutic relevance are not established

---

### Priority 3: **SPP1 as a therapeutic target and prognostic biomarker**
- **Classification**: Therapeutic target / Biomarker
- **Rationale**: SPP1 shows strong prognostic association (HR = 3.40), is mechanistically linked to fibrosis, and is targetable with antibodies or small molecules.
- **Current evidence**: Dataset evidence (high HR), pathway evidence (ECM remodeling, immune modulation), disease-association evidence (consistently elevated in IPF)
- **Supporting evidence**: Preclinical studies show SPP1 neutralization reduces fibrosis in bleomycin models. SPP1 is elevated in IPF plasma and correlates with disease severity.
- **Conflicting evidence**: SPP1 also has roles in tissue repair; complete inhibition may impair healing. Clinical trials of SPP1 inhibitors have not been conducted in IPF.
- **Next steps**: Validate SPP1 protein levels in plasma/lung tissue as a prognostic biomarker; test SPP1-neutralizing antibodies in IPF models; assess SPP1+ cell populations by spatial profiling
- **Conclusion status**: **Supported hypothesis**—strong biological and observational evidence; therapeutic efficacy is speculative and requires testing. **The existence of targeting strategies does not by itself constitute evidence of therapeutic benefit.**

---

### Priority 4: **HGF/MET pathway dysregulation and epithelial-mesenchymal crosstalk**
- **Classification**: Mechanistic hypothesis / Interaction hypothesis
- **Rationale**: Co-elevation of HGF and MET, along with other epithelial-mesenchymal signaling molecules (NRG1, BMP6), suggests that sustained growth factor signaling contributes to failed repair and fibroproliferation.
- **Current evidence**: Dataset evidence (both HGF and MET elevated), pathway evidence (MET signaling), literature evidence (HGF/MET implicated in fibrosis)
- **Conflicting evidence**: HGF is traditionally considered antifibrotic; exogenous HGF reduces fibrosis in some models. The prognostic association of elevated HGF/MET may reflect failed compensatory signaling rather than pathogenic activation.
- **Next steps**: Assess HGF/MET activation status (phospho-MET) in IPF tissue; correlate with epithelial and fibroblast phenotypes; test context-dependent MET inhibition or agonism in models
- **Conclusion status**: **Exploratory hypothesis**—the direction of causality and therapeutic implications are unclear; context-dependent effects require careful mechanistic dissection

---

### Priority 5: **Cell composition versus cell-state changes (confounding check)**
- **Classification**: Confounding or composition check
- **Rationale**: Many risk-associated genes (S100A12, CD177, SELL) are highly cell-type-specific (neutrophils, macrophages, epithelium). The prognostic signal may reflect changes in cell composition (e.g., neutrophil infiltration) rather than transcriptional reprogramming of resident cells.
- **Current evidence**: Dataset evidence (bulk transcriptomics cannot distinguish composition from cell-state changes)
- **Why prioritize**: Distinguishing these possibilities is essential for interpretation and therapeutic targeting. If the signal is driven by infiltrating neutrophils, neutrophil recruitment or activation may be targetable. If it reflects epithelial cell-state changes, epithelial-directed therapies are needed.
- **Next steps**: Deconvolute bulk transcriptomics using reference cell-type signatures (e.g., CIBERSORT, CIBERSORTx); validate by immunohistochemistry or spatial transcriptomics; compare cell composition between good- and poor-prognosis groups
- **Conclusion status**: **Critical confounding check**—must be addressed to ensure valid interpretation of the prognostic signature

---

## 5. Evidence Grounding

### Evidence categories supporting major conclusions:

1. **Direct dataset evidence**: All genes and their hazard ratios, P values, and FDRs (excluding the 10 genes with extreme HRs)

2. **Pathway / ontology evidence**: GO terms (epithelial differentiation, neutrophil chemotaxis, ECM organization), Reactome pathways (MET signaling, neutrophil degranulation), KEGG pathways (chemokine signaling)

3. **Protein interaction evidence**: HGF-MET (ligand-receptor), SLC7A11-SLC3A2 (heterodimer), SPP1-integrin interactions, S100A12-RAGE binding, NRG1-ErbB interactions, MERTK-Gas6 binding

4. **Disease-association evidence**: SPP1, EFEMP1, HTRA1, S100A12 are reported as elevated in IPF lung tissue or serum in multiple independent studies

5. **Expression evidence**: Cell-type-specific markers (S100A12, CD177 for neutrophils; SFTPB, SLC34A2 for alveolar type II cells)

6. **Genetic evidence**: (Limited—none of the genes listed are genome-wide significant IPF risk loci, though MUC5B, not in this list, is)

7. **Clinical evidence**: Neutrophilia in bronchoalveolar lavage predicts poor IPF prognosis (supporting neutrophil signature)

8. **Literature evidence**: Extensive literature on SPP1, HGF/MET, HTRA1, and epithelial dysfunction in IPF

### Independent versus overlapping evidence sources:

- The neutrophil signature is supported by **independent genes** with convergent functions (chemokines, activation markers, adhesion molecules), suggesting robust biological signal rather than artifact from a single highly weighted gene.

- The epithelial signature is supported by genes from **multiple functional categories** (mucins, surfactants, keratins, adhesion molecules), indicating genuine epithelial dysfunction rather than a narrow technical signal.

- Disease-association evidence for SPP1 and EFEMP1 comes from **multiple independent studies** using different platforms and cohorts.

### Conflicting evidence:

- **HGF**: Traditionally considered protective and antifibrotic, yet elevated HGF is associated with poor prognosis in the current dataset. This conflict may reflect:
  - Failed compensatory upregulation
  - Context-dependent signaling (chronic vs. acute)
  - Ligand availability versus receptor activation status

- **SPRY2**: A negative regulator of RTK signaling; its upregulation (HR = 3.26) seems paradoxical if growth factor signaling is pathogenic. Possible explanations:
  - Compensatory feedback in the setting of chronic pathway activation
  - SPRY2 upregulation marks cells experiencing sustained growth factor stimulation
  - Cell-type-specific effects (SPRY2 may have different roles in epithelium vs. mesenchyme)

### Insufficient evidence:

- **Causal directionality**: The dataset provides association, not causation. Whether elevated gene expression drives mortality or reflects advanced disease is unresolved for most genes.

- **Cell-type specificity**: Bulk transcriptomics cannot definitively assign gene expression to specific cell types, limiting mechanistic interpretation.

- **Temporal dynamics**: Cross-sectional transcriptomic analysis cannot reveal whether the signature represents early drivers, late consequences, or ongoing chronic processes.

---

## 6. Limitations and Alternative Explanations

### Limitation 1: **Cell composition versus cell-state changes**
- **Issue**: Many risk-associated genes are enriched in specific cell types (neutrophils, macrophages, epithelial cells). Elevated expression may reflect increased abundance of these cells in fibrotic lung tissue rather than transcriptional reprogramming of resident cells.
- **Implications**: If the prognostic signal is primarily compositional, the biological interpretation shifts from "dysfunctional resident cell states" to "infiltration or expansion of specific cell populations." Therapeutic strategies would differ accordingly (e.g., anti-neutrophil therapies vs. epithelial-directed drugs).
- **How to investigate**: Perform computational deconvolution of bulk RNA-seq data using cell-type reference signatures; validate cell abundance by immunohistochemistry, flow cytometry, or spatial transcriptomics; compare cell composition between good- and poor-prognosis patients.

---

### Limitation 2: **Disease severity and stage confounding**
- **Issue**: The transcriptomic signature may reflect advanced disease stage rather than mechanisms that causally drive mortality. Patients with worse prognosis may have more severe fibrosis, greater functional impairment, or more comorbidities, all of which could influence gene expression independently of causal pathways.
- **Implications**: Some genes may be markers of disease burden rather than therapeutic targets. For example, surfactant gene expression may simply indicate remaining alveolar epithelium in end-stage lungs.
- **How to investigate**: Adjust for clinical cov
